Showing all 3 results

Definition of CHMINACA

CHMINACA refers to a synthetic cannabinoid that has gained significant attention in recent years due to its heightened potency and dangerous effects. Synthetic cannabinoids are human-made substances created to mimic the effects of naturally occurring cannabinoids found in cannabis. CHMINACA, which stands for 5F-CUMYL-PINACA, belongs to the indazole family of synthetic cannabinoids. It exerts its effects by binding to cannabinoid receptors in the brain and nervous system, resulting in psychoactive and mind-altering effects.

CHMINACA is notorious for its high potency, often surpassing that of THC found in natural cannabis. The potency of CHMINACA has raised concerns among health professionals and law enforcement agencies due to its increased risk for toxic effects, including extreme agitation, psychosis, seizures, and even death. As a result, CHMINACA has been classified as a controlled substance in many countries worldwide. The rapid emergence and prevalence of CHMINACA in the illicit drug market pose significant challenges for public health and safety, making it essential for authorities to monitor and regulate this potent synthetic cannabinoid.

History of CHMINACA

CHMINACA, also known as cumyl-CHMINACA or CUMYL-4CN-BINACA, is a synthetic cannabinoid derivative that was first created in the early 21st century. It was developed for research purposes and initially gained popularity in the recreational drug market.

The origins of CHMINACA can be traced back to the early 2000s when it was synthesized by a team of researchers in a laboratory setting. Initially, it was primarily used for scientific research to investigate the effects of cannabinoids on the human body. However, its psychoactive properties soon attracted the attention of the illicit drug market.

In recent years, CHMINACA has gained notoriety due to its association with several incidents of severe intoxication and even death. This has led to its classification as a DEA Schedule I controlled substance, indicating that it has a high potential for abuse and no accepted medical use.

Various modifications and updates have been made to the chemical structure of CHMINACA over time in an attempt to evade legal regulation. However, these modifications have not altered its classification as a controlled substance.

Overall, the history of CHMINACA is intertwined with its development as a cannabinoid derivative and its subsequent illicit use. The creation date of CHMINACA is not specific, but it started gaining attention in the early 2000s.

Legal status of CHMINACA

CHMINACA, specifically AB-CHMINACA, is classified as a DEA Schedule I controlled substance according to the legal status. This categorization is primarily due to its lack of accepted medical use, potential for abuse, and the absence of accepted safety for medical supervision.

Under the Controlled Substances Act (CSA) enforced by the U.S. Drug Enforcement Administration (DEA), substances are classified into different schedules based on their potential for abuse and medical utility. Schedule I substances are considered to have the highest potential for abuse, with no currently accepted medical use in treatment in the United States.

AB-CHMINACA falls under this Schedule I classification due to its lacking recognized medical benefits. Additionally, it is considered to have a high potential for abuse, which poses significant risks to public health and safety. As a result, its distribution, possession, and use are strictly prohibited under federal law.

For reference, the relevant DEA registration number associated with AB-CHMINACA is DEA No. 7031. Additionally, the compound’s CAS number, which serves as a unique identifier for chemical substances, is 1185887-21-1.

In conclusion, the legal status of CHMINACA, specifically AB-CHMINACA, is categorized as a DEA Schedule I controlled substance due to its lack of accepted medical use, potential for abuse, and absence of accepted safety for medical supervision. It is essential to adhere to these regulations to maintain public health and safety.

Chemical Properties of CHMINACA

CHMINACA, also known as cumyl-5F-P7AICA, is a potent synthetic cannabinoid receptor agonist that has gained popularity as a recreational drug. It exhibits fascinating chemical properties that contribute to its effects on the human body. By understanding its chemical properties, one can gain insight into its potency, potential health risks, and its interaction with the endocannabinoid system. This article aims to explore the various chemical properties of CHMINACA and their implications in terms of its biological activity, solubility, stability, and potential for metabolism and elimination within the body. By comprehending these aspects, we can better understand the mechanisms through which CHMINACA exerts its influence on the human body and its potential role as a recreational drug.

Structure of CHMINACA

The structure of CHMINACA plays a crucial role in understanding its relevance to AB-CHMINACA. CHMINACA is a synthetic cannabinoid that is structurally related to AB-CHMINACA, which is a highly potent and widely abused synthetic cannabinoid.

In terms of chemical composition, CHMINACA consists of a core indazole ring, substituted at the 1-position with a cyclohexylmethyl group, and a 3- or 4-aminocarbonyl group at the N-position of the indazole ring. This unique composition sets CHMINACA apart from other synthetic cannabinoids. Additionally, the cyclohexylmethyl group and the aminocarbonyl group contribute to its distinctive functioning.

The functional groups present in CHMINACA are the key determinants of its potency as a cannabinoid derivative. The cyclohexylmethyl group enhances binding to cannabinoid receptors by providing lipophilic interactions with the receptor binding site. This contributes to the increased potency of CHMINACA compared to natural cannabinoids. The presence of the aminocarbonyl group enables hydrogen bonding interactions with the receptor, further enhancing its affinity and efficacy.

Understanding the structure of CHMINACA is important for its relevance to AB-CHMINACA, as both compounds share similar core structures. This similarity in structure implies that AB-CHMINACA may exhibit similar pharmacological effects and potency. Therefore, the structure of CHMINACA is essential in determining its influence on the effects and potency of AB-CHMINACA.

In conclusion, the structure of CHMINACA, comprising an indazole ring substituted with a cyclohexylmethyl group and an aminocarbonyl group, contributes to its potency as a cannabinoid derivative. Its relevance to AB-CHMINACA lies in their shared similar structures, implying similar pharmacological effects and potency.

Synthesis of CHMINACA

The synthesis of CHMINACA involves several key steps and utilizes various reagents and reactions. The process begins with the preparation of the starting materials, which include 4-chlorobenzaldehyde, cyclohexylamine, and a suitable solvent.

The first step in the synthesis is the conversion of 4-chlorobenzaldehyde into the corresponding Schiff base by reacting it with cyclohexylamine. This reaction takes place under mild conditions using a suitable solvent, such as ethanol or methanol. The Schiff base formation is facilitated by the presence of an acid catalyst, such as hydrochloric acid or sulfuric acid.

After the formation of the Schiff base, it is then reduced using a reducing agent like sodium borohydride. This step converts the double bond in the Schiff base to a single bond, resulting in the formation of a secondary amine. The reduction reaction can be carried out in an organic solvent, such as ether or dichloromethane, under reflux conditions.

The final step in the synthesis involves an acid-catalyzed cyclization reaction. This is achieved by adding a Lewis acid, such as aluminum chloride or boron trifluoride, to the reaction mixture. The cyclization reaction converts the secondary amine into a cyclohexane ring, resulting in the formation of CHMINACA.

In summary, the synthesis of CHMINACA involves the conversion of 4-chlorobenzaldehyde into a Schiff base, reduction of the Schiff base, and acid-catalyzed cyclization to form the final product. The key reagents used in the process include cyclohexylamine, sodium borohydride, and a Lewis acid catalyst.

Potency of CHMINACA as a synthetic cannabinoid receptor agonist

CHMINACA is a potent synthetic cannabinoid receptor agonist that exhibits high binding affinity and activation of cannabinoid receptors. It is known to have a strong binding affinity for both CB1 and CB2 receptors, which are the two major types of cannabinoid receptors in the human body. By binding to these receptors, CHMINACA is able to mimic the effects of natural cannabinoids.

The mechanism of action of CHMINACA on the endocannabinoid system involves its interaction with the CB1 and CB2 receptors. When CHMINACA binds to these receptors, it stimulates a cascade of events that ultimately leads to the activation of various signaling pathways, including the inhibition of adenylyl cyclase and the modulation of intracellular calcium levels. This activation of cannabinoid receptors by CHMINACA results in the release of neurotransmitters, such as dopamine, serotonin, and gamma-aminobutyric acid (GABA), which have significant implications for the regulation of various physiological processes.

Within the CHMINACA family, there are several specific synthetic cannabinoids that exhibit high potency as receptor agonists. Some notable examples include MDMB-CHMICA, AB-CHMINACA, and MAB-CHMINACA, which have been found to be even more potent than the parent compound CHMINACA. These compounds have been associated with a range of effects, such as increased heart rate, altered perception, sedation, and euphoria.

In conclusion, CHMINACA is a synthetic cannabinoid receptor agonist that possesses high potency through its strong binding affinity for cannabinoid receptors. Its mechanism of action involves the activation of cannabinoid receptors, leading to the release of neurotransmitters. Additionally, there are various synthetic cannabinoids within the CHMINACA family that exhibit even greater potency as receptor agonists.

Detection and Identification of CHMINACA in Human Samples

The detection and identification of CHMINACA in human samples is crucial in forensic toxicology and drug monitoring. CHMINACA, also known as Cumyl-4CN-BINACA, is a synthetic cannabinoid that belongs to the indazole family. It acts on the same receptors as natural cannabinoids found in marijuana, but its potency and adverse effects are significantly higher. Given its potential for abuse and the associated health risks, accurate and timely detection of CHMINACA in human samples is vital for the prevention and control of its use. This article will discuss the various analytical techniques used for the detection and identification of CHMINACA, including gas chromatography-mass spectrometry (GC-MS), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and immunoassay-based methods. Additionally, it will highlight the challenges and limitations associated with CHMINACA analysis, such as its high structural similarity to other synthetic cannabinoids, and the need for cutoff levels and reference standards to ensure accurate identification and quantification.